iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/38856765/
DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;241(11):2223-2239.
doi: 10.1007/s00213-024-06629-2. Epub 2024 Jun 10.

DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects

Maiko Kitaichi  1   2 , Taro Kato  3 , Hitomi Oki  1 , Ayaka Tatara  1 , Takuya Kawada  1 , Kenji Miyazaki  1 , Chihiro Ishikawa  1 , Katsuyuki Kaneda  2 , Isao Shimizu  1
Affiliations

DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects

Maiko Kitaichi et al. Psychopharmacology (Berl). 2024 Nov.

Abstract

Background: Current treatment of major depressive disorder is facing challenges, including a low remission rate, late onset of efficacy, and worsening severity due to comorbid symptoms such as psychosis and cognitive dysfunction. Serotonin (5-HT) neurotransmission is involved in a wide variety of psychiatric diseases and its potential as a drug target continues to attract attention.

Objectives: The present study elucidates the effects of a novel 5-HT modulator, DSP-6745, on depression and its comorbid symptoms.

Results: In vitro radioligand binding and functional assays showed that DSP-6745 is a potent inhibitor of 5-HT transporter and 5-HT2A, 5-HT2C, and 5-HT7 receptors. In vivo, DSP-6745 (6.4 and 19.1 mg/kg as free base, p.o.) increased the release of not only 5-HT, norepinephrine, and dopamine, but also glutamate in the medial prefrontal cortex. The results of in vivo mouse phenotypic screening by SmartCube® suggested that DSP-6745 has a behavioral signature combined with antidepressant-, anxiolytic-, and antipsychotic-like signals. A single oral dose of DSP-6745 (6.4 and 19.1 mg/kg) showed rapid antidepressant-like efficacy in the rat forced swim test, even at 24 h post-dosing, and anxiolytic activity in the rat social interaction test. Moreover, DSP-6745 (12.7 mg/kg, p.o.) led to an improvement in the apomorphine-induced prepulse inhibition deficit in rats. In the marmoset object retrieval with detour task, which is used to assess cognitive functions such as attention and behavioral inhibition, DSP-6745 (7.8 mg/kg, p.o.) enhanced cognition.

Conclusions: These data suggest that DSP-6745 is a multimodal 5-HT receptor antagonist and a 5-HT transporter inhibitor and has the potential to be a rapid acting antidepressant with efficacies in mitigating the comorbid symptoms of depression.

Keywords: 5-HT; Antidepressant; Antipsychotics; Anxiolytics; Drug discovery.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Abdallah CG, Sanacora G, Duman RS, Krystal JH (2018) The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther 190:148–158. https://doi.org/10.1016/j.pharmthera.2018.05.010 - DOI - PubMed - PMC
    1. Abel KM, Drake R, Goldstein JM (2010) Sex differences in schizophrenia. Int Rev Psychiatry 22:417–428. https://doi.org/10.3109/09540261.2010.515205 - DOI - PubMed
    1. Alexandrov V, Brunner D, Hanania T, Leahy E (2015) High-throughput analysis of behavior for Drug Discovery. Eur J Pharmacol 750:82–89. https://doi.org/10.1016/j.ejphar.2014.11.047 - DOI - PubMed - PMC
    1. Alshaya DS (2022) Genetic and epigenetic factors associated with depression: an updated overview. Saudi J Biol Sci 29:103311. https://doi.org/10.1016/j.sjbs.2022.103311 - DOI - PubMed - PMC
    1. Amidfar M, Kim Y-K (2018) Recent developments on future antidepressant-related serotonin receptors. Curr Pharm Des 24:2541–2548. https://doi.org/10.2174/1381612824666180803111240 - DOI - PubMed

MeSH terms

LinkOut - more resources